RxDoctor Payments Data

Carla Monico, MD

Nephrology · Jackson, MSNPI 1437123825

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 92.2% of the total across 107 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 16 manufacturers reported payments, led by AstraZeneca at 31.4% of the total. Reporting peaked in 2023 at $528 and has fallen 52.0% since, to $254 in 2025.

$2,034in general payments, 2019–2025

Across 107 payments — averaging $19.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$640
  • Aurinia Pharma U.S., Inc.$513
  • Bayer$205
  • Fresenius USA Marketing, Inc.$188
  • Akebia Therapeutics Inc$150
  • Amgen$70
  • plus $269 from 10 others

What the payments were for

  • Food & beverage$1,87592%
  • Education$1598%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,034 in reported general payments places this provider in the 55th percentile of 105 nephrology providers in Mississippi.

See all nephrology providers in Mississippi

Medicare billing

Part B allowed, 2024
$311,833
Medicare patients
550
Services billed
2,213

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VelphoroSucroferric Oxyhydroxide52$122,436
AuryxiaFerric Citrate103$121,881
JardianceEmpagliflozin27$20,355
Sevelamer Carbonate159$19,488
LokelmaSodium Zirconium Cyclosilicate32$16,295
ProcritEpoetin Alfa15$13,428
RenvelaSevelamer Carbonate12$11,729
VeltassaPatiromer Calcium Sorbitex14$10,347
EntrestoSacubitril/Valsartan11$5,276
RetacritEpoetin Alfa-Epbx17$3,636
Colchicine27$1,937
Nifedipine ErNifedipine73$1,531
Allopurinol114$1,104
Torsemide42$1,101
Losartan Potassium128$1,044

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Fresenius USA Marketing, Inc.Velphoro$188$122,43652 claims
Akebia Therapeutics IncAuryxia$150$121,881103 claims
Boehringer IngelheimJardiance$41$20,35527 claims
AstraZenecaLokelma$640$16,29532 claims
NovartisEntresto$19$5,27611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 105 nephrology providers in Mississippi.

Other nephrology in Jackson

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →